Rezolute, Inc. (RZLT)
| Market Cap | 296.73M +12.6% |
| Revenue (ttm) | n/a |
| Net Income | -77.18M |
| EPS | -0.92 |
| Shares Out | 92.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,875,240 |
| Open | 3.060 |
| Previous Close | 3.070 |
| Day's Range | 2.954 - 3.180 |
| 52-Week Range | 1.070 - 11.457 |
| Beta | 0.51 |
| Analysts | Strong Buy |
| Price Target | 9.14 (+185.63%) |
| Earnings Date | Feb 10, 2026 |
About RZLT
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for RZLT stock is "Strong Buy." The 12-month stock price target is $9.14, which is an increase of 185.63% from the latest price.
News
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered...
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating
SAN FRANCISCO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as 90% during intraday trading after the ...
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffere...
SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses in Rezolute to Contact Him Directly to Discuss Their Options If you suffered...
Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all fo...
Alger Small Cap Growth Fund Q4 2025 Portfolio Update
Class A shares of the Alger Small Cap Growth Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Natera, Inc., and Guardant Health, Inc. were...
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffere...
RZLT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses in Rezolute to Contact Him Directly to Discuss Their Options If you suffered...
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options
Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism
Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indications Company plans to meet with FDA to align on path forward for ...
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options
INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffere...
REZOLUTE INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options
RZLT: Rezolute, Inc. Investigated for Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
Rezolute stock fell over 85% on December 11. Block & Leviton is investigating Rezolute for possible securities fraud. Investors should contact the firm.
RZLT INVESTIGATION: Rezolute, Inc. Investors Should Contact Block & Leviton LLP To Potentially Recover Losses
Boston, Massachusetts--(Newsfile Corp. - December 12, 2025) - Block & Leviton is investigating Rezolute, Inc. (NASDAQ: RZLT) for potential securities law violations. Investors who have lost money in t...
Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure
SAN FRANCISCO--(BUSINESS WIRE)--On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as 90% during intraday trading after the company revealed ...
Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT
LOS ANGELES--(BUSINESS WIRE)--Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT.
Rezolute, Inc. (RZLT) Discusses Phase 3 sunRIZE Study Results and Challenges in Congenital Hyperinsulinism Transcript
Rezolute, Inc. (RZLT) Discusses Phase 3 sunRIZE Study Results and Challenges in Congenital Hyperinsulinism Transcript
BREAKING: Rezolute, Inc. Shares Down Over 85%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses
BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Rezolute, Inc. (Nasdaq: RZLT) for potential securities law violations. Investors who have lost money in their Rezolute, Inc. ...
Rezolute's rare disease drug fails main goal in late-stage trial
Rezolute said on Thursday its experimental drug for a rare condition that causes dangerously low blood sugar failed to meet the main goal in a late-stage study.
Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
Study did not meet the primary or key secondary endpoint 45% reduction in hypoglycemia events observed at top ersodetug dose (10 mg/kg) compared to 40% improvement in placebo arm Management to host c...
Rezolute: sunRIZE And upLIFT Trials Could Drive The Next Move
Rezolute is positioned for upside with key catalysts ahead, notably the imminent sunRIZE Phase 3 topline readout for Ersodetug. RZLT maintains a solid $152.2M cash position, supporting a ~23-month run...
Rezolute, Inc. (RZLT) Discusses Clinical Progress and Market Opportunity for Ersodetug in Hyperinsulinism Transcript
Rezolute, Inc. ( RZLT) Discusses Clinical Progress and Market Opportunity for Ersodetug in Hyperinsulinism November 10, 2025 12:00 PM EST Company Participants Christen Baglaneas Nevan Elam - Founder,...
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyper...